AGC Biologics

Contract development and manufacturing for biopharmaceuticals

Bothell, Washington, United States

About AGC Biologics

AGC Biologics specializes in the development and manufacturing of therapeutic proteins, plasmid DNA, viral vectors, and genetically engineered cells for the biopharmaceutical industry. The company provides end-to-end solutions, assisting clients from the initial development stages to full-scale production. Their services are particularly focused on fast-tracking projects for orphan drugs and rare diseases, which often require quicker timelines. AGC Biologics operates a network of advanced facilities across the U.S., Europe, and Asia, all adhering to strict quality regulations known as current Good Manufacturing Practices (cGMP). What sets AGC Biologics apart from competitors is its commitment to continuous innovation and its recent expansion to enhance capabilities in cell and gene therapy. The company's goal is to support biopharmaceutical companies in bringing new treatments to market efficiently and effectively.

Bothell, WashingtonHeadquarters
2001Year Founded
$613MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Risks

Restructuring and layoffs in Colorado indicate potential financial instability.
Leadership changes may disrupt ongoing projects and affect client trust.
Significant investment in Japan could strain financial resources and divert focus.

Differentiation

AGC Biologics specializes in therapeutic proteins, plasmid DNA, and viral vectors.
The company offers fast-track project capabilities for orphan drugs and rare diseases.
AGC Biologics operates globally with facilities in the U.S., Europe, and Asia.

Upsides

Increased demand for plasmid DNA boosts AGC's gene therapy and vaccine services.
Partnership with BioConnection enhances biodrug development capabilities, attracting more clients.
Expansion in Yokohama aligns with growing mRNA and cell therapy demand.

Funding

Total raised$613.00 M
Latest valuation$557.70 M
StageACQUISITION
ACQUISITION
11/30/2016
$558
$557.70 M